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Edited by Robert BaroukiAbstract Human anti-ErbB2 immunoRNase with Erbicin fused
to HP-RNase (ERB-hRNase) is a fully human immunoRNase
made up of human pancreatic RNase fused to a human anti-
ErbB2 scFv. It binds selectively with high aﬃnity to ErbB2-
positive cells, and speciﬁcally inhibits their proliferation,
in vitro and in vivo. An investigation of its mechanism of action
and its intracellular destination has revealed that ERB-hRNase
depends on its RNase activity for cytotoxic action; it reaches
the cytosol directly from the endosomal compartment; it is
inhibited by the cytosolic RNase inhibitor (cRI), but the levels
that ERB-hRNase reaches in the cytosol neutralize cRI, thus
inducing cell death by apoptosis.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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A possible drawback of immunotoxins [1], made up of anti-
bodies fused to toxins, is the immunogenicity and systemic tox-
icity of the bacterial or plant toxins. Therefore, a fully human
immuno-conjugate would be a viable solution for immuno-
therapy. We produced [2] a fully human immunoRNase in
which an RNase substitutes for the toxin of immunotoxins.
The immunoRNase, termed human anti-ErbB2 immuno-
RNase with Erbicin fused to HP-RNase (ERB-hRNase), was
obtained by the fusion of a human anti-ErbB2 scFv called
Erbicin [3] with human pancreatic RNase, an RNase present
in human pancreas and extracellular ﬂuids [4,5]. The chimeric
protein was found to retain the high binding aﬃnity of Erbicin
to ErbB2-positive cells (Kd = 4.5 nM), and the enzymatic
activity of the native RNase.
To date, ERB-hRNase is the only fully human immunoRN-
ase tested with satisfactory results, both in vitro and in vivo,Abbreviations: Erbicin, An anti-ErbB2 scFv; HP-RNase, Huma
pancreatic RNase; IR, ImmunoRNase (scFv-RNase immunoconju
gate); ERB-hRNase, Human anti-ErbB2 immunoRNase with Erbici
fused to HP-RNase; cRI, Cytosolic RNase inhibitor
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eties. Puon ErbB2-positive carcinoma cells. Thus, it is relevant the
understanding of its mechanism of action. The key questions
in this respect are the relevance in the mechanism of the RNase
activity of ERB-hRNase, and its ﬁnal destination to the
cytosol, where the potential RNA targets are. Then, it is also
signiﬁcant the presence in the cytosol of target cells of the
cytosolic RNase inhibitor (cRI), with an extremely high
aﬃnity (Kd < 1fM) for monomeric RNases such as HP-RNase
[6]. It has been reported [7] that a cytotoxic immunoRNase,
made up of human RNase 2 fused to a murine single
chain antibody to the transferrin receptor, is surprisingly
inhibited by the cytosolic RNase inhibitor, even though its
cytotoxic action depends on the integrity of its RNA degrading
activity.
Thus we investigated: (i) the role of the RNase activity of
ERB-hRNase in the mechanism of its antitumor action; (ii)
the ﬁnal destination of ERB-hRNase in the target cells; (iii)
the eﬀects of the cytosolic RNase inhibitor on the RNA
degrading and cytotoxic activities of ERB-hRNase; (iv) the
nature of cell death as induced by ERB-hRNase.2. Materials and methods
2.1. Antibodies and cell cultures
The antibodies were: IgGs from a rabbit anti-HP-RNase antiserum
and from a rabbit anti-cRI antiserum (both from Igtech, Salerno,
Italy) puriﬁed by aﬃnity chromatography on protein A-Sepharose
CL-4B (Amersham Pharmacia Biotech); mouse anti-EEA1 antibody
(early endosomal antigen-1, from BD Transduction Lab. N.J.,
USA); mouse anti-human golgin-97 antibody (Molecular Probes, Lei-
den NL); horseradish peroxidase (HRP) conjugated goat anti-rabbit
IgG (Pierce, Rockford, IL); Alexa Fluor 488 goat-anti rabbit and
Alexa Fluor 546 goat anti-mouse antibodies from Molecular Probes.
SKBR3 cells (from ATCC, Rockville, MD) were cultured in RPMI
1640 (Gibco BRL) with 10% fetal bovine serum, 50 Units/ml penicillin,
and 50 lg/ml streptomycin (all from Gibco BRL).
2.2. RNase activity, inhibition and inactivation
RNase activity was tested with the acid-insoluble RNA precipitation
test described in [8] on yeast RNA (8 mg/ml). For inhibition assays,
appropriate amounts of ERB-hRNase were preincubated with increas-
ing concentrations of cRI at 37 C for 10 min prior to the activity test
described above. Ribonuclease inhibitor was purchased from Promega
(Madison, WI, USA); its concentration was determined as previously
described [9].
RNase inactivation was obtained as previously described [10] by
incubation of the RNase in the dark with bromoacetic acid (25 mM)
at 35 C. After suitable time intervals aliquots were analyzed for their
residual RNase activity with the test described above.blished by Elsevier B.V. All rights reserved.
Fig. 1. Eﬀects of the enzymatic inactivation of ERB-hRNase on its
cytotoxic activity. ErbB2-positive SKBR3 cells were treated in
triplicate for 72 h with ERB-hRNase before (black circles), or after
alkylation with bromoacetic acid (white circles).
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Active or inactivated proteins (10–70 nM) were added to SKBR3
cells seeded in 96-well plates at a density of 1.5 · 104/well in 150 ll.
At suitable time intervals surviving cells were counted in triplicate
using the Trypan-Blue (Sigma) exclusion test. Cell survival is expressed
as percent of viable cells in the presence of the protein under test, with
respect to control cultures grown in the absence of the protein. Typi-
cally, standard deviations were below 10%.
SKBR3 cell lysates, prepared as previously described [11], were
ultracentrifuged at 206000·g for 1 h at 4 C to obtain the cytosolic
fraction. Protein concentration was determined by the Bradford colori-
metric assay (Sigma), and aliquots of 20 lg were run on 12% SDS–
PAGE, followed by electroblotting onto PVDF membranes (Millipore
Corporation, Bedford, MA, USA).
Cytosolic ERB-hRNase and cRI were detected with anti-HP-RNase
or anti-cRI IgGs, respectively, followed by goat anti-rabbit HRP-con-
jugated IgGs. The signal from secondary antibodies was visualized by
enhanced chemiluminescence detection (ECL western blotting detec-
tion kit, Amersham Biosciences). The signal intensity of reactive bands
was quantitatively measured with a phosphorimager (GS-710, Biorad,
Hercules, CA, USA).
Apoptotic death was tested by Annexin V-FITC and propidium
iodide staining as previously described [11] on SKBR3 cells seeded in
6-well plates at a density of 6 · 105 and incubated for 24 h at 37 C
with ERB-hRNase (50 nM). Cell cycle analyses were performed as
described [11] after 72 h of incubation. Labelled cells were analyzed
by the FACS Calibur ﬂow cytometer (Becton Dickinson). The percent-
age of cells in each phase of the cell cycle (G1, S and G2/M) was
calculated by using Modﬁt software (Becton Dickinson).
2.4. Immunoﬂuorescence and confocal microscopy studies
Cells grown on coverslips in 24-well plates to 60% conﬂuency were
incubated with ERB-hRNase (15 lg/ml) for 16 h at 37 C, washed,
ﬁxed with 4% formaldehyde for 20 min at room temperature and
permeabilized as described elsewhere [12]. The analysis of immunoﬂu-
orescence was performed with a confocal laser scanner Zeiss 510LSM,
equipped with Argon ionic laser whose k was set-up to 488 nm, a HeNe
laser whose k was set-up to 543 nm and immersion oil objective
63·/1.4f. Emission of ﬂuorescence was revealed by BP 505–530 band
pass ﬁlter for Alexa-488 and 560 Long Pass for Alexa 546. Images
for the double staining immunoﬂuorescence were acquired simulta-
neously in the green and red channels with a resolution of 1024 ·
1024 pixel.3. Results
3.1. Eﬀects of inactivation of the RNase activity on the
cytotoxic activity of ERB-hRNase
To determine whether the antitumor action of ERB-hRNase
depends on its ribonuclease activity, the protein was inacti-
vated by alkylation with bromoacetic acid. Under the condi-
tions employed [10] bromoacetic acid reacts selectively with
the active-site histidine residues of pancreatic RNases, thus
causing enzyme inactivation.
After 16 h of incubation of ERB-hRNase with 25 mM
bromoacetic acid at 35 C, the enzymatic activity was com-
pletely lost, as determined by RNase activity assays, whereas
its binding ability was only slightly aﬀected as determined by
ELISA assays (data not shown). The inactivated protein was
tested on SKBR3 cells, while the native, untreated protein
was used as a control. As shown in Fig. 1, after a 72 h incuba-
tion no eﬀects on cell survival were detected when inactivated
ERB-hRNase was tested at concentrations up to 70 nM,
whereas the native, enzymatically active protein was found
to be as cytotoxic as expected [2].
These results indicate that the RNase activity is essential for
the cytotoxic action of ERB-hRNase: once deprived of its
enzymatic function, it also looses its cytotoxic power.3.2. Intracellular pathway of ERB-hRNase
The ability of the immunoRNase to be internalized by
ErbB2-positive cells was already suggested by a previous ana-
lysis [2]. Here, the investigation was aimed at tracing all the
steps of its pathway from the extracellular space to the cytosol.
SKBR3 cells grown on coverslips were treated with ERB-
hRNase (15 lg/ml) for 16 h at 37 C, then tested with an
anti-HP-RNase antibody followed by a secondary antibody
(see Methods). As shown in Fig. 2A, ERB-hRNase was found
to bind to the cell surface of SKBR3 cells. The ﬂuorescence
could be removed by washing the cells with a stripping, high
salt (1 M NaCl) glycine buﬀer at pH 2.0 (see Fig. 2B). When
SKBR3 cells, incubated with ERB-hRNase as described
above, then stripped of surface-bound protein, were ﬁxed, per-
meabilized and treated with the antibodies as above, a strong
intracellular staining was localized in vesicles (Fig. 2C). No
staining was detected in untreated control cells incubated with
primary and secondary antibodies (Fig. 2D). The intracellular
vesicles in which ERB-hRNase was internalized were identiﬁed
as early endosomes because their pattern of distribution
(Fig. 2E) was quite superimposable with the staining
(Fig. 2F) obtained with an antibody against EEA-1, a protein
known to be localized in early endosomes [13]. Fig. 2G shows
in yellow the superimposition of the images illustrated in
Fig. 2E and F.
To clarify the further progressing of ERB-hRNase in the
cell, its localization in the Golgi apparatus was tested with
an antibody directed to golgin-97, a peripheral membrane pro-
tein exposed on the cytosolic face of the Golgi structure. In
these experiments no localization of ERB-hRNase in the Golgi
apparatus was detectable (data not shown).
These ﬁndings suggested that ERB-hRNase takes a direct
route from endosomes to the cytosol, as reported for other tox-
ins such as diphtheria toxin [14]. To verify this possibility, the
cytotoxic action of ERB-hRNase was measured in the presence
of nigericin and monensin [14,15], carboxylic ionophores that
raise the endosomal pH and consequently inhibit the trans-
location of the toxins to the cytosol [14]. SKBR3 cells were
treated for 72 h with either ionophore alone (5 nM) or with
the immunoRNase alone (80 nM), or with the combination of
each ionophore with ERB-hRNase at the same concentrations.
The results of these experiments (see Fig. 3A) indicate that
both monensin and nigericin, although moderately cytotoxic
Fig. 2. Binding and internalization of ERB-hRNase in SKBR3 cells as
visualized by confocal microscopy with an anti-HP-RNase antibody,
followed by a ﬂuorescein-conjugated secondary antibody. Cells incu-
bated in the absence (panels B and D) or in the presence of the
immunoRNase for 16 h (panels A and C) were washed without
permeabilization (panels A and B) or stripped and permeabilized
(panels C and D). To determine the localization of ERB-hRNase in
endosomes, SKBR3 cells, treated with ERB-hRNase for 16 h, were
washed, permeabilized, and stained as above (panel E), or with an anti-
early endosome antigen-1 antibody followed by secondary antibody
(panel F). In panel G cells treated with both antibodies are shown. Bar
represents 10 lm.
Fig. 3. Eﬀects of ionophores on the cytotoxicity and intracellular level
of ERB-hRNase. (A) Cytotoxicity of ERB-hRNase tested (three
experiments) on SKBR3 cells in the absence or presence of monensin
or nigericin. (B) Cytosolic levels of ERB-hRNase in cells treated with
nigericin, as determined by western blotting analyses with an anti-HP-
RNase antibody (upper panel). In the lower panel: the relative
histogram constructed by normalizing to 100% the values obtained in
the absence of nigericin after 2 and 16 h, respectively.
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presumably by interfering with its route to the cytosol.
This conclusion was further validated by analyzing the level
of ERB-hRNase in the cytosol of cells treated with the protein
in the absence or in the presence of nigericin. SKBR3 cells,
treated with the immunoRNase (80 nM) for 2 h or 16 h at
37 C, in the absence or in the presence of nigericin (5 nM),
were stripped of surface-bound protein with the glycine/NaCl
buﬀer, and lysed. Equal amounts of cytosolic proteins from
cell lysates, as determined by the Bradford assay, were ana-
lyzed by western blotting using anti-HP-RNase IgGs. As
shown in Fig. 3B, the treatment with nigericin signiﬁcantly re-duced the level of ERB-hRNase in the cytosol, with a drastic
reduction (92% after 16 h) with respect to the level observed
in cells treated with ERB-hRNase alone.
In conclusion, internalized ERB-hRNase is directly trans-
located from endosomes to the cytosol, as inactivation of the
endosomal function blocks its access to the cytosol and its
cytotoxic action.
3.3. Eﬀects of cRI on the enzymatic activity of ERB-hRNase
To investigate the role of cRI in ERB-hRNase cytotoxicity,
enzymatic assays were carried out in the absence or in the
presence of increasing concentrations of cRI. As shown in
Fig. 4, the catalytic action of the immunoRNase is completely
Fig. 4. Eﬀects of cRI on the enzymatic activity of ERB-hRNase.
Inhibition by cRI of the catalytic action of ERB-hRNase immuno-
RNase (IR) was measured at increasing cRI/IR ratios.
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ratio of about 1.
In order to understand why ERB-hRNase is eﬃcient in caus-
ing cell toxicity, despite its sensitivity to cytosolic RNase inhib-
itor, we investigated the cRI content in SKBR3 cells and the
molar ratio of endogenous cRI to endocytosed ERB-hRNase.
The cytosolic levels of ERB-hRNase and cRI were measured
in SKBR3 cells treated with the immunoRNase (100–200 nM)
for 2 h at 37 C, then stripped of surface-bound protein with
the glycine/NaCl buﬀer and lysed. Aliquots of the cell lysates
were used to prepare the cytosolic fraction by ultracentrifuga-
tion. Equal protein amounts of both whole cell lysates and
cytosolic fractions were analyzed by immunoblotting using
either anti-cRI or anti-HP-RNase IgGs. The signal intensity
of positive bands was estimated on calibration curves obtained
by phosphorimaging the signals of cRI and immunoRNase
used as standard proteins. Fig. 5 shows that the level of intra-
cellular ERB-hRNase in treated cells is at least two-fold higher
than that of the endogenous cytosolic inhibitor.
These ﬁndings indicate that the concentration of immuno-
RNase which permeates the cytosol exceeds that of endoge-
nous cRI, thus explaining why ERB-hRNase can display its
full cytotoxic action although it is sensitive to cRI.Fig. 5. Intracellular levels of ERB-hRNase and endogenous cRI. The
levels in the cytosol of ERB-hRNase and endogenous cytosolic
inhibitor (cRI) were measured (three experiments) by immunoblotting
with an anti-RNase (upper panel) and an anti-cRI antibody (lower
panel). Lanes 1–3 (both panels): aliquots of 40, 80 and 160 ng of
reference proteins; Lanes 4–5: immunoreactive proteins in the cytosolic
fraction of cells treated with ERB-hRNase (100 nM, lane 4; 200 nM,
lane 5).3.4. Determination of the nature of cell death induced by
ERB-hRNase and its eﬀects on cell cycle
To determine whether the nature of cell death occurs
through induction of apoptosis, we used annexin V to measure
the appearance of phosphatidylserine, a marker of apoptosis,
on the outer leaﬂet of the plasma membrane of SKBR3 cells.
Cells treated with ERB-hRNase for 24 h were found to be
stained by FITC-conjugated annexin V in a higher percentage
(22%) than untreated cells (4%). These results indicate that the
nature of cell death as induced by ERB-hRNase is apoptotic.
To test whether a growth arrest also contributes to the anti-
tumor action of ERB-hRNase, SKBR3 cells were incubated in
the absence or in the presence of the immunoRNase for 72 h at
37 C, and then subjected to cell cycle analysis by ﬂow cyto-
metry. ERB-hRNase was found to signiﬁcantly reduce the
percentage of SKBR3 cells undergoing S-phase (6.9%) with
respect to control untreated cells (16.6%), and produces an
accumulation of cells in G0/G1 phase (88.7% versus 63.6%).4. Discussion
In this paper we report that the antitumor action of ERB-
hRNase is based on its RNA degrading activity. Hence, it acts
as an immuno-pro-toxin, as its RNase-based toxic action is not
exerted unless the chimeric protein is drawn inside the cell by
its immune moiety. Furthermore, when it is not allowed to
reach the cytosol, where potential RNA targets are, ERB-
hRNase cannot express its cytotoxic action.
The ﬁnding that the enzymatic activity of ERB-hRNase is
inhibited by cRI, the cytosolic RNase inhibitor, could be sur-
prising, as in the case of another immunoRNase [7]. Here,
however, we provide an explanation of the apparent conun-
drum of the absolute requirement of the RNase activity of
ERB-hRNase, and its sensitivity to the inhibition by cRI.
We report that the concentration in the cytosol of endogenous
cRI is readily neutralized by the amounts of ERB-hRNase that
reach the cytosol. Consistent with the above results are our
ﬁndings that ERB-hRNase induces apoptosis and inhibits cell
cycle progression in ErbB2-positive cells.
These results not only shed light on the mechanism of the
antitumor action of the human ERB-hRNase investigated
here, but oﬀer also a basis for the rational design of second-
generation immunoRNases with improved properties as anti-
tumor agents.
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